RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer

This study is testing a targeted drug called a RET inhibitor as a pre-surgery (neoadjuvant) treatment for patients with locally advanced thyroid cancer that has a specific genetic change called a RET alteration. The goal is to shrink the tumor before surgery to make it easier to remove. **You may be eligible if...** - You are 14 years or older - You have been diagnosed with locally advanced thyroid cancer (confirmed by pathology) - Your tumor has a RET gene alteration (fusion or mutation) - Your cancer meets criteria for "locally advanced" (e.g., invading nearby structures or with large lymph nodes) **You may NOT be eligible if...** - Your thyroid cancer does not have a RET alteration - Your cancer is not locally advanced (it is early stage or already widely metastatic) - You have serious organ problems that prevent you from taking the study drug Talk to your doctor to see if this trial is right for you.